ReviewInternational journal of molecular sciences2023
Apigenin: A Therapeutic Agent for Treatment of Skin Inflammatory Diseases and Cancer.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 88 citations in OpenAlex.
- Trial
- GC-Ms, UHPLC-MS/MSChemistry & biodiversity · 2026Article
- Review
- Research Progress and Prospects of Flavonoids in the Treatment of Diseases by Regulating Autophagy: A Narrative Review.Molecules (Basel, Switzerland) · 2026Review
- Comparison of Selected Pro-Health Biologically Active Chemical Compounds inMolecules (Basel, Switzerland) · 2026Article
- The Therapeutic Potential of Polyphenols in Modulating Barrier Lipids, Microbiome Interactions, and Inflammatory Pathways in Atopic Dermatitis.Nutrients · 2026Review
- Integrated metabolite profiling and molecular docking reveal anti-aging potential of Clerodendrum infortunatum L. fractions.Scientific reports · 2026Article
- Botanical and Upcycled Bioactives for Advanced Topical Formulations: Mechanistic Pathways, Cutaneous Delivery, and Sustainability-by-Design.Pharmaceutics · 2026Review
- Nanocarriers, Smart Biomaterials and Emerging Therapeutics for Psoriasis: Current Progress and Future Directions.AAPS PharmSciTech · 2026Review
- Article
- Mechanistic Insights into Flavonoids in Cosmetic Applications: Multifunctional Roles and Formulation Considerations.Clinical, cosmetic and investigational dermatology · 2026Review
- Harnessing Antioxidant Properties of Plant-Derived Bioactive Compounds to Alleviate Atopic Dermatitis Symptoms: A Review.Current pharmaceutical design · 2026Review
- Overcoming the Low Bioavailability of Apigenin: The Therapeutic Efficacy for Androgenetic Alopecia Through Topical Administration.Food science & nutrition · 2025Article
- Chemical composition and in vitro bioactivities of hydroalcoholic extracts from Turnera pumilea, Hyptis lantanifolia, and Ageratina popayanensis cultivated in Colombia.Scientific reports · 2025Article
- Research Progress and Prospects of Flavonoids in the Treatment of Hyperlipidemia: A Narrative Review.Molecules (Basel, Switzerland) · 2025Review
- A Stroll Through Saffron Fields, Cannabis Leaves, and Cherry Reveals the Path to Waste-Derived Antimicrobial Bioproducts.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Formulation and Evaluation of Liposome-Encapsulated Phenolic Compounds from Olive Mill Waste: Insights into Encapsulation Efficiency, Antioxidant, and Cytotoxic Activities.Molecules (Basel, Switzerland) · 2025Article
- Bioactive Potential of Sweet Cherry (Foods (Basel, Switzerland) · 2025Article
- Brazilian Organic Honeydew Reduces In Vitro and In Vivo Periodontal Disease-Related Subgingival Biofilm.Foods (Basel, Switzerland) · 2025Article
- Exploring the therapeutic potential of phytochemicals apigenin and ellagic acid in managing polycystic ovarian syndrome and its comorbidities: a comprehensive review.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The skin is the main barrier between the body and the environment, protecting it from external oxidative stress induced by ultraviolet rays. It also prevents the entrance of infectious agents such as viruses, external antigens, allergens, and bacteria into our bodies. An overreaction to these agents causes severe skin diseases, including atopic dermatitis, pruritus, psoriasis, skin cancer, and vitiligo. Members of the flavonoid family include apigenin, quercetin, luteolin, and kaempferol. Of these, apigenin has been used as a dietary supplement due to its various biological activities and has been shown to reduce skin inflammation by downregulating various inflammatory markers and molecular targets. In this review, we deal with current knowledge about inflammatory reactions in the skin and the molecular mechanisms by which apigenin reduces skin inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.